S. Taubmann, H.G. Alt / Journal of Organometallic Chemistry 693 (2008) 1808–1814
1813
4.3.3. Compound 1c
(CH), 31.4 (CH2), 30.5 (CH2). MS data for 2a: 409 (MÅ+)
From 354 mg (1 mmol) of 1-[(4-brom-2,6-dimethyl-
phenyl)imino]methylenyl]-2-naphthalenol, 24 mg (1 mmol)
of NaH, and 336 mg (0.5 mmol) [Ir(cod)Cl]2 was obtained
490 mg (0.75 mmol, 75%) of 1c as a yellow powder. Spec-
troscopic data for 1c: 1H NMR (250 MHz, 21 °C, CDCl3):
9.00 (s, 1H), 7.90–7.22 (m, 8H), 4.48 (s, br, 2H), 2.62–2.53
(m, 2H), 2.28 (s, 6H), 2.20–2.14 (m, 4H), 1.80–1.64 (m,
4H). 13C {1H} (62 MHz, 21 °C, CDCl3): 166.6 (Cq), 157.5
(CH), 149.0 (Cq), 136.6 (CH), 134.3 (Cq), 131.1 (CH),
129.3 (CH), 127.8 (CH), 127.3 (Cq), 125.5 (CH), 123.2
(CH), 119.3 (Cq), 118.9 (CH), 110.4 (Cq), 70.4 (CH), 68.9
(CH), 32.8 (CH2), 29.7 (CH2), 18.6 (CH3), 18.5 (CH3).
MS data for 1c: 653 (MÅ+) (100), 623 (7), 573 (7), 541
(10), 295 (9).
(17), 407 (20), 375 (39), 296 (20), 269 (9), 108 (100).
4.4.2. Compound 2b
From 146 mg (1 mmol) of 8-hydroxyquinaldine, 24 mg
(1 mmol) of NaH, and 336 mg (0.5 mmol) [Ir(cod)Cl]2
was obtained 305 mg (0.73 mmol, 73%) of 2b as an orange
1
powder. Spectroscopic data for 2b: H NMR (250 MHz,
21 °C, CDCl3): 8.00 (d, 1H), 7.27 (dd, 1H), 7.01 (dd, 1H),
6.93 (dd, 1H), 6.78 (dd, 1H), 4.43 (s, 2H), 4.11 (s, 2H),
2.50 (s, 3H), 2.29–2.21 (m, 4H), 1.61–1.50 (m, 4H). 13C
{1H} (62 MHz, 21 °C, CDCl3): 161.7 (Cq), 144.3 (Cq),
140.0 (CH), 129.4 (CH), 128.7 (Cq), 124.1 (CH), 115.8
(CH), 113.5 (CH), 67.2 (CH), 55.4 (CH), 33.8 (CH2), 29.6
(CH2), 23.8 (CH3). MS data for 2b: 459 (MÅ+) (100), 457
(75), 429 (55), 294 (13), 269 (6).
4.3.4. Compound 1d
From 275 mg (1 mmol) of 1-[[(2,3-dimethylphenyl)
imino]methylenyl]-2-naphthalenol, 24 mg (1 mmol) of
NaH, and 336 mg (0.5 mmol) [Ir(cod)Cl]2 was obtained
488 mg (0.85 mmol, 85%) of 1d as a yellow powder. Spec-
troscopic data for 1d: 1H NMR (250 MHz, 21 °C, CDCl3):
9.13 (s, 1H), 7.89–6.89 (m, 9H), 5.49–4.42 (m, 2H), 3.19–
3.16 (m, 2H), 2.67–2.61 (m, 4H), 3.34 (s, 3H), 2.21 (s,
3H), 1.78–1.59 (m, 4H). 13C {1H} (62 MHz, 21 °C, CDCl3):
166.3 (Cq), 157.4 (CH), 151.1 (Cq), 137.6 (Cq), 136.3 (CH),
129.2 (CH), 134.4 (Cq), 129.8 (Cq), (Cq), 128.2 (CH), 127.9
(CH), 127.6 (CH), 127.4 (Cq), 125.4 (CH), 122.9 (CH),
122.1 (CH), 119.1 (CH), 110.0 (Cq), 69.0 (CH), 56.7
(CH), 32.4 (CH2), 29.6 (CH2), 20.6 (CH3), 14.3 (CH3).
MS data for 1d: 575 (MÅ+) (100), 573 (70), 545 (8), 463
(25), 295 (17), 77 (10).
4.4.3. Compound 2c
From 137 mg (1 mmol) of 3-pyridinepropanol, 24 mg
(1 mmol) of NaH, and 336 mg (0.5 mmol) [Ir(cod)Cl]2
was obtained 196 mg (0.45 mmol, 45%) of 2c as an orange
1
powder. Spectroscopic data for 2c: H NMR (250 MHz,
21 °C, CDCl3): 8.35–8.33 (m, 1H), 7.55–7.43 (m, 1H),
7.05–7.02 (m, 1H), 7.00–6.95 (m, 1H), 3.55 (t, 2H), 3.27
(s, 2H), 2.81 (t, 2H), 2.35 (s, 2H), 1.85–1.81 (m, 2H), 1.37
(s, 4H), 1.11 (s, 4H).
4.5. General procedure for the synthesis of N-carboxylate
iridium complexes (3)
The respective carbonic acid (1 mmol) was dissolved in
10 ml THF by heating. The solvent was added to a solu-
tion of 0.5 mmol [Ir(cod)(OMe)]2 in 10 ml THF. The
mixture was stirred for 3 h at RT. A color change from
yellow to red resp. brown was observed. After reducing
the solvent in vacuo, the precipitated solid was filtered,
washed with pentane and diethylether and dried in
vacuo. The products were obtained as red and brown
powders.
4.4. General procedure for the synthesis of N-alcoholate
iridium complexes (2)
A Schlenk tube was charged with 1 mmol of the respec-
tive alcoholate and 5 ml THF. After addition of 1 mmol
NaH, the mixture was stirred for 2 h at RT. The suspension
was slowly added to a solution of 0.5 mmol [Ir(cod)Cl]2 in
10 ml THF and stirred for 1 h at RT. The solvent was
removed in vacuo and the crude product was dissolved in
CH2Cl2. After filtration through Na2SO4, the solvent was
reduced in vacuo until a solid precipitated. The solid was
washed with pentane and diethylether and dried in vacuo.
The products were obtained as yellow and orange powders.
4.5.1. Compound 3a
From 486 mg (2.5 mmol) of 2-pyridine acetic acid and
662 mg (1 mmol) [Ir(cod)OMe]2 was obtained 859 mg
(0.98 mmol, 98%) of 3a as an orange powder. Spectro-
1
scopic data for 3a: H NMR (250 MHz, 21 °C, CDCl3):
8.40 (d, 1H), 7.82 (dd, 1H), 7.40–7.36 (m, 1H), 7.05–7.02
(m, 1H), 4.61 (s, 2H), 4.18–4.16 (m, 2H), 3.11–3.09 (m,
2H), 2.21–2.14 (m, 4H), 1.62–1.57 (m, 4H). 13C {1H}
(62 MHz, 21 °C, CDCl3): 171.0 (Cq), 156.0 (Cq), 148.5
(CH), 139.2 (CH), 126.3 (CH), 125.2 (CH), 79.2 (CH),
46.1 (CH2), 45.1 (CH2). MS data for 3a: 453 (MÅ+ÀH)
(3), 297 (100), 295 (98), 269 (26), 91 (4), 77 (7).
4.4.1. Compound 2a
From 109 mg (1 mmol) of hydroxymethylpyridine,
24 mg (1 mmol) of NaH, and 336 mg (0.5 mmol)
[Ir(cod)Cl]2 was obtained 91 mg (0.23 mmol, 23%) of 2a
1
as a yellow powder. Spectroscopic data for 2a: H NMR
(250 MHz, 21 °C, CDCl3): 8.76 (d, 1H), 8.09 (d, 1H),
7.81 (dd, 1H), 7.05 (d, 1H), 4.61 (s, 2H), 4.17 (s, 2H),
3.10 (s, 2H), 2.21–2.14 (m, 4H), 1.62–1.57 (m, 4H). 13C
{1H} (62 MHz, 21 °C, CDCl3): 148.1 (CH), 136.9 (CH),
121.7 (CH), 120.0 (CH), 68.4 (CH), 63.7 (CH2), 53.3
4.5.2. Compound 3b
From 137 mg (1 mmol) of 6-picolinic-acid and 331 mg
(0.5 mmol) [Ir(cod)OMe]2 was
obtained 415 mg
(0.95 mmol, 95%) of 3b as an orange powder. Spectro-